Christina Gewinner, PhDUniversity College London 2012 Skacel Family Scholar Identification of novel drug targets for INPP4B-deficient ovarian tumours Dr. Gewinner’s lab has previously identified a gene called inositol polyphosphate 4-phosphatase type II (INPP4B) which no longer functions in approximately 40% of ovarian tumors. Patients with such tumors have poor survival rates. She has demonstrated that INPP4B […]
Read MoreBarbara Norquist, MDUniversity of Washington2013 Skacel Family Scholar Genes Contributing to Hereditary Ovarian Cancer in BRCA1/2 Wildtype Families Nearly a quarter of ovarian cancer cases may be caused by inherited mutations, with a significant portion caused by mutations in genes other than BRCA1 and BRCA2 (BRCA1/2). Next generation sequencing techniques have made it possible to […]
Read MoreCapucine Van Rechem, PhDMassachusetts General Hospital2014 Skacel Family Scholar Copy Gain and Resistance: Uncovering Roles for Epigenetic Regulation in Ovarian Cancer A major issue in the treatment of ovarian cancer is the development of resistance to standard chemotherapy. Such drug resistance has been linked to the gain of a specific genomic region, 1q12-1q21. Dr. Van […]
Read MoreErin George, MDUniversity of Pennsylvania2016 Skacel Family Scholar Targeting the ATR/CHK1 pathway in high grade serous ovarian cancer with ATR inhibitors New treatments are needed for recurrent ovarian cancer, a subset of which is more aggressive than the original cancer and has no effective treatment. Aggressive recurrent cancers rely on DNA repair pathways, involving proteins […]
Read MoreAchuth Padmanabhan, PhDBaylor College of Medicine2019 Skacel Family Scholar PROTAC-mediated degradation of oncogenic gain-of-function p53 mutants: A personalized therapeutic strategy for ovarian cancer Ovarian cancer is the fifth leading cause for cancer-associated deaths among women in the US and is associated with frequent mutations in p53 gene. While some mutations result in the loss of […]
Read More